Data backs splanchnic ablation procedure from Axon Therapies

The Satera ablation cathether. [Image courtesy of Axon Therapies]Axon Therapies today announced positive six-month results from a trial for its proprietary splanchnic ablation for volume management (SAVM) therapy.

Dr. Marat Fudim, advanced heart failure specialist at Duke University Medical Center, presented results at the Technology and Heart Failure Therapeutics (THT) Conference in Boston. The data came from a roll-in cohort for the REBALANCE-HF investigational device exemption feasibility trial.

Santa Clara, California-based Axon Therapies said its data remains consistent with prior results for the SAVM therapy. The novel, frontline therapy uses an outpatient ablation procedure. It aims to rebalance volume distribution for heart failure patients with preserved ejection fraction (HFpEF).

In addition to the positive results, Axon Therapies said it expects its trial to reach full enrollment by the end of the month. The approximately 120-patient study should…

Read more
  • 0